Specifications

Variant Details
Catalog IDbs-13370R-Cy5-100ULSupplier Catalog IDbs-13370R-Cy5-100UL
Size100 µlPrice N/A
Supplier N/A Package Content GLDC Polyclonal Antibody, Cy5 Conjugated, 100ul
General
AntigenGLDCClonalityPolyclonal
HostRabbitReactivityHuman, Mouse, Rat
ApplicationsImmunofluorescence, ImmunohistochemistryConjugatedConjugated
Conjugate TypeCy (Cyanine)Specific ConjugateCy5
IsotypeIgGImmunogenKLH conjugated synthetic peptide derived from human GLDC
Concentration1µg/µlDilutionIF(IHC-P)(1:50-200)
Purification MethodPurified by Protein A.GeneGLDC
Gene ID2731 (Homo sapiens)Storage & HandlingStore at 4°C for 12 months
Storage BufferAqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide

Description

The glycine cleavage system is comprised of AMT (known as Protein T), GCSH (known as Protein H), DLD (known as Protein L) and GLDC (known as Protein P), all of which work together to catalyze the cleavage and degradation of glycine. GLDC (glycine dehydrogenase ), also known as GCE, GCSP (glycine cleavage system P protein) or HYGN1, is a 1,020 amino acid protein that localizes to the mitochondria and belongs to the gcvP family. GLDC binds to glycine and enables the methylamine group from glycine to be transferred to the Protein T. GLDC exists as a homodimer and utilizes pyridoxal phosphate as a cofactor. Mutations in the gene encoding GLDC leads to nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy (GCE), an autosomal recessive disease characterized by accumulation of a large amount of glycine in body fluid and by severe neurological symptoms.

For research use only.

Resources

Protocol

Article

Protocol

Safety

Brochure

Handbook

Publication

Validation